Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 22 articles:
HTML format



Single Articles


    August 2022
  1. KIM B, Jung M, Moon KC, Han D, et al
    Quantitative proteomics identifies TUBB6 as a biomarker of muscle-invasion and poor prognosis in bladder cancer.
    Int J Cancer. 2022 Aug 27. doi: 10.1002/ijc.34265.
    PubMed     Abstract available


    July 2022
  2. XIONG J, Yang L, Deng YQ, Yan SY, et al
    The causal association between smoking, alcohol consumption and risk of bladder cancer: A univariable and multivariable Mendelian randomization study.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34228.
    PubMed     Abstract available


    February 2022
  3. DIANATINASAB M, Wesselius A, Salehi-Abargouei A, Yu EYW, et al
    Dietary fats and their sources in association with the risk of bladder cancer: A pooled analysis of 11 prospective cohort studies.
    Int J Cancer. 2022 Feb 19. doi: 10.1002/ijc.33970.
    PubMed     Abstract available


    January 2022
  4. KARANOVIC S, Ardin M, Tang Z, Tomic K, et al
    Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.
    Int J Cancer. 2022;150:374-386.
    PubMed     Abstract available


    September 2021
  5. OLAH C, Hahnen C, Nagy N, Musial J, et al
    A qPCR-based method for molecular subtype classification of urinary bladder cancer - stromal gene expressions show higher prognostic values than intrinsic tumor genes.
    Int J Cancer. 2021 Sep 18. doi: 10.1002/ijc.33809.
    PubMed     Abstract available


  6. LAI H, Cheng X, Liu Q, Luo W, et al
    Single-cell RNA sequencing reveals the epithelial cell heterogeneity and invasive subpopulation in human bladder cancer.
    Int J Cancer. 2021 Sep 3. doi: 10.1002/ijc.33794.
    PubMed     Abstract available


    March 2021
  7. TREVISANI F, Di Marco F, Raggi D, Bettiga A, et al
    Renal function outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the pure-01 study.
    Int J Cancer. 2021 Mar 15. doi: 10.1002/ijc.33554.
    PubMed     Abstract available


    February 2021
  8. VAN DOEVEREN T, Nakauma-Gonzalez JA, Mason AS, van Leenders GJLH, et al
    The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder.
    Int J Cancer. 2021;148:981-987.
    PubMed     Abstract available


    January 2021
  9. KOUTROS S, Decker KL, Baris D, Pardo LA, et al
    Bladder Cancer Risk Associated with Family History of Cancer.
    Int J Cancer. 2021 Jan 27. doi: 10.1002/ijc.33486.
    PubMed     Abstract available


    October 2020
  10. OZGUN G, Senturk S, Erkek-Ozhan S
    Retinoic acid signaling and bladder cancer: Epigenetic deregulation, therapy and beyond.
    Int J Cancer. 2020 Oct 31. doi: 10.1002/ijc.33374.
    PubMed     Abstract available


  11. WIECZOREK E, Garstka MA
    Recurrent Bladder Cancer in Aging Societies: Importance of Major Histocompatibility Complex Class I Antigen Presentation.
    Int J Cancer. 2020 Oct 26. doi: 10.1002/ijc.33359.
    PubMed     Abstract available


    July 2020
  12. ZHOU Q, Zhang H, Wang Z, Zeng H, et al
    Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer.
    Int J Cancer. 2020 Jul 31. doi: 10.1002/ijc.33237.
    PubMed     Abstract available


    June 2020
  13. DIANATINASAB M, Wesselius A, Salehi-Abargouei A, Yu EYW, et al
    Adherence to a Western dietary pattern and risk of bladder cancer: a pooled analysis of 13 Cohort Studies of the Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) International Study.
    Int J Cancer. 2020 Jun 24. doi: 10.1002/ijc.33173.
    PubMed     Abstract available


  14. XU T, Li HT, Wei J, Li M, et al
    Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype.
    Int J Cancer. 2020;146:3065-3076.
    PubMed     Abstract available


    May 2020
  15. LI Y, Hendryx MS, Xun P, He K, et al
    Physical activity and risk of bladder cancer among postmenopausal women.
    Int J Cancer. 2020 May 10. doi: 10.1002/ijc.33042.
    PubMed     Abstract available


  16. SJODAHL G, Eriksson P, Patschan O, Marzouka NA, et al
    Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma.
    Int J Cancer. 2020;146:2636-2647.
    PubMed     Abstract available


    April 2020
  17. HIEN TT, Ambite I, Butler D, Wan MLY, et al
    Bladder cancer therapy without toxicity - A dose-escalation study of alpha1-oleate.
    Int J Cancer. 2020 Apr 22. doi: 10.1002/ijc.33019.
    PubMed     Abstract available


  18. JOCHEMS SHJ, Reulen RC, van Osch FHM, Witlox WJA, et al
    Fruit consumption and the risk of bladder cancer: a pooled analysis by the BLadder cancer Epidemiology and Nutritional Determinants study.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33008.
    PubMed     Abstract available


    December 2019
  19. POTTEGARD A, Kristensen KB, Friis S, Hallas J, et al
    Urinary tract infections and risk of squamous cell carcinoma bladder cancer: A Danish nationwide case-control study.
    Int J Cancer. 2019 Dec 21. doi: 10.1002/ijc.32842.
    PubMed     Abstract available


    November 2019
  20. VRIELING A, Bueno-De-Mesquita HB, Ros MM, Kampman E, et al
    One-carbon metabolism biomarkers and risk of urothelial cell carcinoma in the European prospective investigation into cancer and nutrition.
    Int J Cancer. 2019;145:2349-2359.
    PubMed     Abstract available


    October 2019
  21. ZENG H, Liu Z, Wang Z, Zhou Q, et al
    Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses.
    Int J Cancer. 2019 Oct 4. doi: 10.1002/ijc.32715.
    PubMed     Abstract available


  22. JACK S, Madhivanan K, Ramadesikan S, Subramanian S, et al
    A Novel, Safe, Fast, Efficient Treatment for Her2-positive and Negative Bladder Cancer Utilizing an EGF-Anthrax Toxin Chimera.
    Int J Cancer. 2019 Oct 4. doi: 10.1002/ijc.32719.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: